During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the recommended regimens and trials supporting therapies following lenalidomide-refractory relapse of multiple myeloma in the second article of a 2-part series.
CRISTIANA COSTA CHASE, DO: The National Comprehensive Cancer Network [NCCN] guidelines break it down by [whether] they were on bortezomib [Velcade] or lenalidomide [Revlimid] as their maintenance and what you are expecting them to be refractory to. In this particular scenario…category 1 options [include] daratumumab [Darzalex], carfilzomib [Kyprolis], and dexamethasone; daratumumab, bortezomib, and dexamethasone; and isatuximab [Sarclisa], carfilzomib, and dexamethasone [Isa-Kd].1
There are other regimens that would be considered. I don’t use liposomal doxorubicin very often; there is infusion chemotherapy that I reach for [in some] patients, but that’s usually a different scenario. Carfilzomib plus dexamethasone [Kd]…I tend not to reach for that kind of therapy. For a lenalidomide-refractory patients, elotuzumab [Empliciti], lenalidomide, and dexamethasone is perhaps not the best pairing, but there are pomalidomide [Pomalyst] and selinexor [Xpovio] regimens. I think selinexor is a great drug. I know not everybody feels great about it. The way it was used as monotherapy was extremely toxic, but I like it as a once-weekly drug and we use a lot of it.
How do you approach evaluating the trials of the category 1 regimens for lenalidomide-refractory RRMM?
We get a median progression-free survival [PFS] of about 5.5 years after [first-line lenalidomide, bortezomib, dexamethasone] and autologous stem cell transplant.2 But we know with each subsequent relapse, myeloma becomes more resistant, PFS becomes shorter, and responses become lower.
Maybe the best way to break down [the trials] is to look at the median PFS that we may expect with single agents [plus dexamethasone in the comparator arms of these trials]. With pomalidomide and dexamethasone [Pd] from the ICARIA-MM [NCT02990338] and the APOLLO [NCT03180736] studies, we may expect a median PFS of 6 to 7 months for these patients,3,4 and for patients receiving bortezomib plus dexamethasone [Vd], another 7 months [based on CASTOR (NCT02136134) and OPTIMISMM (NCT01734928)].5,6 Carfilzomib, being a more potent proteasome inhibitor, as a single agent we may get 15 to 20 months median PFS [based on CANDOR (NCT03158688)].7 So what we‘re looking at is what can we pair these drugs with, and how can we improve those numbers, if that‘s what we are expecting.
We have several different studies. We havethe IKEMA trial [NCT03275285], which was for isatuximab, also a CD38 monoclonal antibody. The No. 1 question I get is, what makes it different [from daratumumab]? It targets a different epitope. I have a lot of times where I love using isatuximab for a couple of very specific instances…. But the IKEMA data are extremely impressive. Without trying to cross-compare the median PFS in this particular study, 41.7 months is fairly impressive [in the context of] 28, 24, 16, 11, 12, and 11 months median PFS [in the experimental arms of the CANDOR, CASTOR, ICARIA-MM, APOLLO, and OPTIMISMM trials, respectively].3-8
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Tolerability Helps Decide Third-Line Treatment in Advanced RCC
April 30th 2024During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.
Read More